Drug Trial Radar · NCT05092958
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
654
Planned (sponsor's estimate)
Start
Jun 3, 2022
Primary completion
Jul 15, 2029
Study completion Jul 15, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Oct 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and avelumab together may further shrink the cancer or prevent it from returning/progressing.
Conditions
- Advanced Bladder Urothelial Carcinoma
- Advanced Renal Pelvis Urothelial Carcinoma
- Advanced Ureter Urothelial Carcinoma
- Advanced Urethral Urothelial Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Renal Pelvis Urothelial Carcinoma
- Metastatic Ureter Urothelial Carcinoma
- Metastatic Urethral Urothelial Carcinoma
- Stage III Bladder Cancer AJCC v8
- Stage III Renal Pelvis and Ureter Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Renal Pelvis and Ureter Cancer AJCC v8
- Stage IV Renal Pelvis Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
Interventions
AvelumabDrug
Given IV
Biospecimen CollectionProcedure
Undergo collection of blood and urine samples
Bone ScanProcedure
Undergo bone scan
Cabozantinib S-malateDrug
Given PO
Computed TomographyProcedure
Undergo CT
Magnetic Resonance ImagingProcedure
Undergo MRI
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Time from randomization until death due to any cause, assessed up to 5 years
Locations
275 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital in Arizona
Phoenix, Arizona
Sutter Auburn Faith Hospital
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Memorial Medical Center
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Sutter Roseville Medical Center
Roseville, California
Sutter Medical Center Sacramento
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
California Pacific Medical Center-Pacific Campus
San Francisco, California
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California
Sutter Solano Medical Center/Cancer Center
Vallejo, California
Beebe South Coastal Health Campus
Millville, Delaware
Helen F Graham Cancer Center
Newark, Delaware
Medical Oncology Hematology Consultants PA
Newark, Delaware
Beebe Health Campus
Rehoboth Beach, Delaware
MedStar Washington Hospital Center
Washington D.C., District of Columbia
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Mayo Clinic in Florida
Jacksonville, Florida
Cleveland Clinic-Weston
Weston, Florida
Rush-Copley Medical Center
Aurora, Illinois
Advocate Good Shepherd Hospital
Barrington, Illinois
Illinois CancerCare-Bloomington
Bloomington, Illinois
Illinois CancerCare-Canton
Canton, Illinois
Illinois CancerCare-Carthage
Carthage, Illinois
Centralia Oncology Clinic
Centralia, Illinois
Northwestern University
Chicago, Illinois
Rush MD Anderson Cancer Center
Chicago, Illinois
University of Illinois
Chicago, Illinois
Advocate Illinois Masonic Medical Center
Chicago, Illinois
AMG Crystal Lake - Oncology
Crystal Lake, Illinois
Carle at The Riverfront
Danville, Illinois
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois
Illinois CancerCare-Dixon
Dixon, Illinois
Advocate Good Samaritan Hospital
Downers Grove, Illinois
Carle Physician Group-Effingham
Effingham, Illinois
Crossroads Cancer Center
Effingham, Illinois
Showing 40 of 275 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.